Market closed
GeneDx Holdings/$WGS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About GeneDx Holdings
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
Ticker
$WGS
Sector
Trading on
Industry
Health Care Providers & Services
Headquarters
Employees
1,000
Website
GeneDx Holdings Metrics
BasicAdvanced
$2.6B
-
-$1.94
2.08
-
Price and volume
Market cap
$2.6B
Beta
2.08
52-week high
$115.60
52-week low
$6.79
Average daily volume
1.3M
Financial strength
Current ratio
3.611
Quick ratio
3.262
Long term debt to equity
46.007
Total debt to equity
47.368
Interest coverage (TTM)
-7.08%
Management effectiveness
Return on assets (TTM)
-3.20%
Return on equity (TTM)
-22.10%
Valuation
Price to revenue (TTM)
8.437
Price to book
10.86
Price to tangible book (TTM)
30.73
Price to free cash flow (TTM)
-75.823
Growth
Revenue change (TTM)
50.79%
Earnings per share change (TTM)
-73.11%
3-year revenue growth (CAGR)
12.91%
3-year earnings per share growth (CAGR)
-70.39%
GeneDx Holdings News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Accesswire·2 days ago
GeneDx Holdings Corp. (WGS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Accesswire·3 days ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GeneDx Holdings Corp. - WGS
Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for GeneDx Holdings stock?
GeneDx Holdings (WGS) has a market cap of $2.6B as of February 23, 2025.
What is the P/E ratio for GeneDx Holdings stock?
The price to earnings (P/E) ratio for GeneDx Holdings (WGS) stock is 0 as of February 23, 2025.
Does GeneDx Holdings stock pay dividends?
No, GeneDx Holdings (WGS) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next GeneDx Holdings dividend payment date?
GeneDx Holdings (WGS) stock does not pay dividends to its shareholders.
What is the beta indicator for GeneDx Holdings?
GeneDx Holdings (WGS) has a beta rating of 2.08. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.